A Trivalent HSV-2 gC2, gD2, gE2 Nucleoside-Modified mRNA-LNP Vaccine Provides Outstanding Protection in Mice against Genital and Non-Genital HSV-1 Infection, Comparable to the Same Antigens Derived from HSV-1
Kevin P. Egan(University of Pennsylvania), Harvey M. Friedman(University of Pennsylvania), Lauren M. Hook(University of Pennsylvania), Sita Awasthi(University of Pennsylvania), Drew Weissman(California University of Pennsylvania), Mohamad‐Gabriel Alameh(Children's Hospital of Philadelphia), Bernard T. Fowler(University of Pennsylvania), Mitchell Beattie(Acuitas Therapeutics (Canada)), Giulia Tebaldi(University of Pennsylvania), Alexis M. Naughton(University of Pennsylvania), Gary H. Cohen(University of Pennsylvania)
Cited by 28
Related Papers
mRNA vaccines — a new era in vaccinology
|Nature Reviews Drug Discovery|2018|4.4k
CAR T Cells Produced in vivo to Treat Cardiac Injury
|HAL (Le Centre pour la Communication Scientifique Directe)|2023|940
Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses
|Immunity|2021|713
An ionizable lipid toolbox for RNA delivery
|Nature Communications|2021|581
Nanomaterial Delivery Systems for mRNA Vaccines
|Vaccines|2021|546